单参数、基于结构的IsoPSA检测在检出任何前列腺癌和高级别前列腺癌方面的诊断准确性优于基于总前列腺特异性抗原浓度的检测:一项初步报告
多中心前瞻性研究纳入261例计划前列腺活检的男性,评估IsoPSA检测的诊断准确性。IsoPSA对任何前列腺癌的ROC曲线下面积为0.79,对高级别前列腺癌为0.81;决策曲线分析显示其净获益优于不活检、全部活检及改良前列腺癌预防试验风险计算器2.0。在推荐活检的切点,IsoPSA使假阳性活检减少48%;在识别高级别疾病低风险的切点,假阳性率降低45%。
要点
- IsoPSA对任何前列腺癌的ROC曲线下面积为0.79,对高级别前列腺癌为0.81。
- 在推荐活检的切点,IsoPSA使假阳性活检减少48%。
- 在识别高级别疾病低风险的切点,IsoPSA使假阳性率降低45%。
核心结论
- 基于结构的IsoPSA检测优于基于浓度的PSA测量,并较其他方案提供净获益。
- 一旦经过验证,IsoPSA的临床应用可能显著减少不必要的活检,同时识别需要治疗的患者。
研究设计与样本
- 多中心前瞻性研究,纳入261例计划前列腺活检的男性,来自美国五个学术和社区中心,入组时间为2015年8月至2016年12月。
主要发现
- 任何前列腺癌的总体患病率为53%,高级别前列腺癌为34%。
- 任何前列腺癌 vs 无癌的ROC曲线下面积为0.79,高级别前列腺癌 vs 低级别前列腺癌/良性组织的ROC曲线下面积为0.81。
- 决策曲线分析显示,IsoPSA较不活检、全部活检和改良前列腺癌预防试验风险计算器2.0具有更优的净获益。
- 在推荐活检的切点,IsoPSA使假阳性活检减少48%;在识别高级别疾病低风险的切点,假阳性率降低45%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称本研究为初步研究(preliminary study),并指出IsoPSA需经验证后方可临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IsoPSA is a serum-based assay that predicts prostate cancer (PCa) risk by partitioning isoforms of prostate-specific antigen (PSA) with an aqueous two-phase reagent. OBJECTIVES: To determine the diagnostic accuracy of IsoPSA in identifying the presence or absence of PCa and the presence of high-grade disease in a contemporary biopsy cohort. DESIGN, SETTING, AND PARTICIPANTS: Multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the USA enrolled between August 2015 and December 2016. INTERVENTION: Performance of the IsoPSA assay. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Discrimination power was evaluated using receiver operating characteristic (ROC) analysis. The outcome of the IsoPSA assay was transformed into risk probability using logistic regression. Decision curve analysis (DCA) was used to compare the net benefit of IsoPSA against other clinical protocols. RESULTS AND LIMITATIONS: The overall prevalence was 53% for any PCa and 34% for high-grade PCa. The area under the ROC curve was 0.79 for any cancer versus none and 0.81 for high-grade PCa versus low-grade PCa/benign histology. In this preliminary study, DCA revealed a superior net benefit of IsoPSA against no biopsy, all biopsy, and the modified Prostate Cancer Prevention Trial Risk Calculator 2.0. At a cutoff selected to recommend biopsy, IsoPSA demonstrated a 48% reduction in false-positive biopsies; at a cutoff selected to identity men at low risk of high-grade disease, there was a 45% reduction in the false-positive rate. CONCLUSION: The structure-based IsoPSA assay outperformed concentration-based PSA measurement, and provided a net benefit against other protocols. Once validated, clinical use of IsoPSA could significantly reduce unnecessary biopsies while identifying patients needing treatment. PATIENT SUMMARY: The IsoPSA assay outperformed prostate-specific antigen in predicting the overall risk of prostate cancer and the risk of clinically significant cancer in a preliminary study. The IsoPSA assay could assist in determining the need for prostate biopsy for patients.
引用
- Klein EA, Chait A, Hafron JM, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol. 2017. PMID: 28396176. doi:10.1016/j.eururo.2017.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。